查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1467904

2024-2032 年充血性心臟衰竭藥物市場（依藥物類別、給藥途徑、配銷通路及地區分類）

Congestive Heart Failure Drugs Market by Drug Class, Route of Administration, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年全球充血性心臟衰竭藥物市場規模達85億美元。肥胖和心血管問題的盛行率上升、老年人口的增加和不健康的飲食習慣是推動市場發展的一些關鍵因素。

充血性心臟衰竭是一種影響心肌泵血能力的疾病。一般由高血壓、冠狀動脈心臟病、糖尿病、肥胖、過量飲酒等引起。其症狀包括躺下時呼吸短促、虛弱、疲勞、腹部、足部和腳踝腫脹、夜間頻尿、噁心和注意力不集中。可以透過保持健康的體重、保持身體活動以及控制血壓和血糖水平來預防。除此之外，還可以使用各種處方藥物來控制，這些藥物有助於預防血栓、擴張血管、加強心臟收縮和改善心臟功能。目前，ACE抑制劑、血管擴張劑、洋地黃糖苷、利尿劑和BETA受體阻斷劑是最常使用的充血性心臟衰竭藥物。其中，ACE抑制劑可防止血管緊張素的形成，血管緊張素會導致血管收縮，而BETA受體阻斷劑則可阻止某些化學物質的作用。

目前，全球老年人口不斷增加，極易罹患糖尿病和慢性心血管疾病，這是積極影響市場的主要因素之一。此外，過度吸煙和飲酒，加上個人不健康的飲食習慣，會增加心臟病的風險，從而刺激了全球對充血性心臟衰竭藥物的需求。再加上由於肥胖和缺乏體力活動而導致的心臟問題的發生率上升，目前正在加強市場的成長。此外，人們對早期診斷和治療心臟病的好處的認知不斷增強，這為市場創造了積極的前景。除此之外，對有效藥物和治療的需求不斷成長以及授權機構的批准為領先的市場參與者提供了利潤豐厚的成長機會。此外，各國政府為改善醫療基礎設施並為患者提供最佳護理所採取的措施也促進了市場的成長。此外，醫院和住宅區藥房的擴張以及新興的電子商務行業以實惠的價格提供便捷的藥品，以及安全的線上支付方式的設施預計將推動市場的成長。

本報告回答的關鍵問題

  • 全球充血性心臟衰竭藥物市場有多大？
  • 2024-2032年全球充血性心臟衰竭藥物市場的預期成長率是多少？
  • 推動全球充血性心臟衰竭藥物市場的關鍵因素是什麼？
  • COVID-19 對全球充血性心臟衰竭藥物市場有何影響？
  • 根據藥物類別，全球充血性心臟衰竭藥物市場的詳細情形如何？
  • 根據給藥途徑，全球充血性心臟衰竭藥物市場的詳細情形如何？
  • 全球充血性心臟衰竭藥物市場基於配銷通路的詳細情形如何？
  • 全球充血性心臟衰竭藥物市場的關鍵區域有哪些？
  • 全球充血性心臟衰竭藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球充血性心臟衰竭藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依藥物類別

  • ACE抑制劑
    • 市場走向
    • 市場預測
  • 血管張力素 2 受體阻斷劑
    • 市場走向
    • 市場預測
  • BETA受體阻斷劑
    • 市場走向
    • 市場預測
  • 利尿劑
    • 市場走向
    • 市場預測
  • 醛固酮拮抗劑
    • 市場走向
    • 市場預測
  • 正性肌力藥
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依管理途徑

  • 口服
    • 市場走向
    • 市場預測
  • 靜脈
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥局
    • 市場走向
    • 市場預測
  • 網路藥局
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AstraZeneca plc
    • Bayer AG
    • Boehringer Ingelheim International GmbH (CH Boehringer Sohn Ag & Co. KG)
    • Novartis AG
Product Code: SR112024A6649

The global congestive heart failure drugs market size reached US$ 8.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 22.6 Billion by 2032, exhibiting a growth rate (CAGR) of 11.17% during 2024-2032. The rising prevalence of obesity and cardiovascular problems, increasing geriatric population and unhealthy dietary habits represent some of the key factors driving the market.

Congestive heart failure is a medical condition that affects the pumping ability of the heart muscle. It is generally caused by hypertension, coronary artery disease, diabetes, obesity, and excessive alcohol consumption. Its symptoms include shortness of breath while lying down, weakness, fatigue, swelling in the abdomen, feet, and ankles, frequent urination at night, nausea, and difficulty in concentration. It can be prevented by maintaining a healthy weight, staying physically active, and controlling blood pressure and glycemic levels. Besides this, it is controlled using various prescribed drugs that help prevent blood clots, expand blood vessels, strengthen the contractions of the heart, and improve heart functioning. At present, ACE inhibitors, vasodilators, digitalis glycosides, diuretics, and beta-blockers are some of the most prescribed congestive heart failure drugs. Amongst these, ACE inhibitors prevent the formation of angiotensin, which causes blood vessels to constrict, and beta blockers block the actions of certain chemicals.

Presently, the increasing global geriatric population, which is highly susceptible to diabetes and chronic cardiovascular diseases, represents one of the major factors positively influencing the market. In addition, excessive smoking and drinking of alcoholic beverages, coupled with unhealthy dietary habits of individuals, increases the risks of heart problems, which is catalyzing the demand for congestive heart failure drugs across the globe. This, coupled with the rising occurrence of heart problems due to obesity and lack of physical activity, is currently strengthening the growth of the market. Furthermore, the increasing awareness among individuals about the benefits of early diagnosis and treatment of heart disease is creating a positive outlook for the market. Apart from this, the escalating demand for effective drugs and treatment and their approval from authorized agencies offer lucrative growth opportunities to the leading market players. Moreover, initiatives undertaken by governments of various countries to improve healthcare infrastructure and provide optimal care to patients are contributing to the growth of the market. Additionally, the expansion of pharmacies in hospitals and residential areas and the burgeoning e-commerce industry providing easy availability of medicines at affordable rates and the facility of secured online payment methods are expected to propel the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global congestive heart failure drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration, and distribution channel.

Drug Class Insights:

ACE Inhibitors

Angiotensin 2 Receptor Blockers

Beta Blockers

Diuretics

Aldosterone Antagonists

Inotropes

Others

The report has also provided a detailed breakup and analysis of the congestive heart failure drugs market based on the drug class. This includes ACE inhibitors, angiotensin 2 receptor blockers, beta blockers, diuretics, aldosterone antagonists, inotropes, and others. According to the report, ACE inhibitors represented the largest segment.

Route of Administration Insights:

Oral

Intravenous

A detailed breakup and analysis of the congestive heart failure drugs market based on the route of administration has also been provided in the report. This includes oral and intravenous. According to the report, the oral route of administration accounted for the largest market share.

Distribution Channel Insights:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the congestive heart failure drugs market based on the route of administration has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (The United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa. According to the report, North America was the largest market for congestive heart failure drugs. Some of the factors driving the North America market included the development of healthcare infrastructure, increasing cases of heart failure and the easy availability of technologically advanced devices and innovative drugs.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global congestive heart failure drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG), Novartis AG, etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global congestive heart failure drugs market?
  • 2. What is the expected growth rate of the global congestive heart failure drugs market during 2024-2032?
  • 3. What are the key factors driving the global congestive heart failure drugs market?
  • 4. What has been the impact of COVID-19 on the global congestive heart failure drugs market?
  • 5. What is the breakup of the global congestive heart failure drugs market based on the drug class?
  • 6. What is the breakup of the global congestive heart failure drugs market based on the route of administration?
  • 7. What is the breakup of the global congestive heart failure drugs market based on the distribution channel?
  • 8. What are the key regions in the global congestive heart failure drugs market?
  • 9. Who are the key players/companies in the global congestive heart failure drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Congestive Heart Failure Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 ACE Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Angiotensin 2 Receptor Blockers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Beta Blockers
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Diuretics
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Aldosterone Antagonists
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Inotropes
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intravenous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Novartis AG
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report

List of Figures

  • Figure 1: Global: Congestive Heart Failure Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Congestive Heart Failure Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Congestive Heart Failure Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 5: Global: Congestive Heart Failure Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Congestive Heart Failure Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Congestive Heart Failure Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Congestive Heart Failure Drugs (ACE Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Congestive Heart Failure Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Congestive Heart Failure Drugs (Angiotensin 2 Receptor Blockers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Congestive Heart Failure Drugs (Angiotensin 2 Receptor Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Congestive Heart Failure Drugs (Beta Blockers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Congestive Heart Failure Drugs (Beta Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Congestive Heart Failure Drugs (Diuretics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Congestive Heart Failure Drugs (Diuretics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Congestive Heart Failure Drugs (Aldosterone Antagonists) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Congestive Heart Failure Drugs (Aldosterone Antagonists) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Congestive Heart Failure Drugs (Inotropes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Congestive Heart Failure Drugs (Inotropes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Congestive Heart Failure Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Congestive Heart Failure Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Congestive Heart Failure Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Congestive Heart Failure Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Congestive Heart Failure Drugs (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Congestive Heart Failure Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Congestive Heart Failure Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Congestive Heart Failure Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Congestive Heart Failure Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Congestive Heart Failure Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Congestive Heart Failure Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Congestive Heart Failure Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Congestive Heart Failure Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Congestive Heart Failure Drugs Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Congestive Heart Failure Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Congestive Heart Failure Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 82: Global: Congestive Heart Failure Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Congestive Heart Failure Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Congestive Heart Failure Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Congestive Heart Failure Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Congestive Heart Failure Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Congestive Heart Failure Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Congestive Heart Failure Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Congestive Heart Failure Drugs Market: Competitive Structure
  • Table 7: Global: Congestive Heart Failure Drugs Market: Key Players